Broadening the Treatment Horizon: Examining the Expanding Roles of New Therapies in Epilepsy Management

Program Description

Recent advances in the understanding of the genetics of epilepsy have led to new insights that stand to significantly improve treatment for individual patient presentations and needs. With several anti-seizure medications (ASMs) now approved (e.g., cannabidiol, fenfluramine, ganaxolone) for syndromes with expanding indications, genetic testing may impact treatment decisions for a large population of patients. To help improve the diagnostic journeys of patients and set clinicians on the right path to optimal treatment decision-making, this educational program focuses on employing modern strategies for timely and accurate diagnosis and personalized management of epilepsy. Drs. Joseph Sullivan, Scott Perry, and Sudha Kessler lead learners through an interactive exploration of several of their own real patient cases. Throughout the activity, learners are invited to weigh in on how they might think through these same scenarios before the faculty reveals what actually happened alongside supporting evidence to illustrate their modern application of these evolving considerations.

Target Audience

The target audience for this initiative includes adult and pediatric neurologists, epileptologists, geneticists, and advanced practice professionals involved in the long-term management of patients with epilepsy.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Evaluate clinical indicators for and logistical considerations (e.g., test diagnostic power) for guiding the pursuit of genetic testing in epilepsy to ensure early and accurate diagnosis
  • Identify the current and potential roles of newer FDA-approved agents (e.g., cannabidiol, fenfluramine, ganaxolone) to determine how and for whom these agents may be best utilized
  • Examine published research data and real-world evidence with modern ASMs to better counsel appropriate patients regarding their known benefits and risks
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

   Joseph E. Sullivan, MD, FAES (Chair)
   Murphy Parker Endowed Professorship in Pediatric Epilepsy
   Professor of Neurology & Pediatrics
   University of California San Francisco (UCSF)
   Director, UCSF Pediatric Epilepsy Center of Excellence
   UCSF Benioff Children’s Hospitals
   San Francisco, CA
   Sudha K. Kessler, MD, MSCE
   Associate Professor of Neurology and Pediatrics
   Perelman School of Medicine at the
   University of Pennsylvania
   Children’s Hospital of Philadelphia
   Philadelphia, PA
   Scott Perry, MD
   Head of Neurosciences and Director,
   Jane and John Justin Institute for Mind Health
   Medical Director, Genetic Epilepsy Clinic,
   Cook Children’s Medical Center
   Fort Worth, TX

This activity is jointly provided by  Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.


Accreditation Statement

This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

Purdue designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

Conflicts of Interest Disclosure Policy

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity. 
All relevant conflicts of interest have been mitigated prior to the start of the activity.
None of the planners, reviewers, Efficient LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.
Planners’ and Managers’ Disclosures
All additional planning committee members, staff and reviewers of Efficient LLC and Purdue University College of Pharmacy have no relationships to disclose.
Faculty Disclosures
Dr. Sullivan reported the following financial relationships:
  • Consulting Fees: Asceneuron, BrightMinds, Encoded Therapeutics, Epilepsy Study Consortium, Epygenix Therapeutics, Inviatae, Knopp Biosciences, Longboard, Stoke Therapeutics Greenwich Biosciences, Supernus, Xenon Pharmaceuticals
  • Fees for Non-CE Services: BioPharm, Encoded Therapeutics, Marinus Pharmaceuticals, Stoke Therapeutics, Zogenix
  • Ownership Interest: Epygenix Therapeutics

Dr. Kessler reported the following financial relationships:

  • Consulting Fees: Jazz Pharmaceuticals, Marinus Pharmaceuticals, Takeda Pharmaceuticals

Dr. Perry reported the following financial relationships:

  • Consulting Fees: Biomarin, Bright Minds, Cycle Pharmaceuticals, Eisai, Encoded Therapeutics, Greenwich Bioscences, Marinus, Neurelis, Stoke Therapeutics, Zogenix
  • Speakers Bureau: Greenwhich Biosciences, NobelPharma

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

Supported by an educational grant from Jazz Pharmaceuticals.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance


Please login or register to take this course.